Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FURIN | P09958 | 3/20 | 0.49 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | ACACB | O00763 | 2/20 | 0.35 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.35 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.34 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.33 |
| ▸ | FFAR4 | Q5NUL3 | 5/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16291678 | 1.00 | FURIN (0.49) | FURINPARP10EPHX2ALDH1A1TSHR | |
| SCHEMBL16292008 | 1.00 | FURIN (0.49) | FURINPARP10EPHX2ALDH1A1TSHR | |
| SCHEMBL16308651 | 1.00 | FURIN (0.49) | FURINPARP10EPHX2ALDH1A1TSHR | |
| SCHEMBL20217186 | 1.00 | FURIN (0.49) | FURINPARP10EPHX2ALDH1A1TSHR | |
| SCHEMBL256373 | 0.83 | PARP10 (0.53) | FURINPARP10EPHX2ALDH1A1TSHR | |
| SCHEMBL20217187 | 0.83 | FURIN (0.49) | FURINPARP10EPHX2ALDH1A1TSHR | |
| SCHEMBL19921733 | 0.83 | FURIN (0.49) | FURINPARP10EPHX2FFAR4 | |
| SCHEMBL6575789 | 0.80 | FURIN (0.46) | FURINPARP10EPHX2CHEK2SLC6A2 | |
| SCHEMBL5375836 | 0.80 | FURIN (0.46) | FURINPARP10EPHX2CHEK2SLC6A2 | |
| SCHEMBL5383373 | 0.80 | FURIN (0.46) | FURINPARP10EPHX2CHEK2SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2766352-B1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIV HEALTH NETWORK UHN (CA) | 2018-06-06 | — | — | EP | disclosed |
| US-9580390-B2 | Indazole compounds as kinase inhibitors and method of treating cancer with same | UNIVERSITY HEALTH NETWORK (CA) | 2017-02-28 | — | — | US | disclosed |
| US-20140371202-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | UNIVERSITY HEALTH NETWORK (CA) | 2014-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371202-A1 | INDAZOLE COMPOUNDS AS KINASE INHIBITORS AND METHOD OF TREATING CANCER WITH SAME | PLK4, PLK2, PLK3 | FURIN 4451/4885PARP10 1870/4885EPHX2 4770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.